Germany: More living space for Berlin - EIB lends EUR 240 million to Gewobag
14 January 2020
The European Investment Bank (EIB) is providing the state-owned housing company Gewobag with a 240-million-euro loan, which is earmarked for the construction of 2,000 new residential units by 2023. The new buildings will predominantly meet “energy-efficient house” standards and therefore surpass the requirements of the applicable energy saving regulation (EnEV).
The contract for financing the project between the European Investment Bank and Gewobag was already signed. This cooperation will secure further affordable housing for Berlin.
“The low-interest loan from the EIB enables us to make further investments in Berlin’s housing construction in order to increase the state’s own residential portfolio. This also means that our tenants’ rental burdens are kept as low as possible. We are pleased to have a strong partner on our side with the EIB”, says Markus Terboven, member of the board of Gewobag.
“The lack of quality, affordable housing is a pressing issue in many European cities," said Ambroise Fayolle, EIB Vice-President responsible for operations in Germany. "I am proud that the EIB has a long tradition in financing sustainable urban housing. Our loan to Gewobag brings more financially accessible and greener homes to many people in Berlin, and when we talk about the added value that a public bank like the EIB needs to deliver, this is a prime example.”
This loan is already the second financing project on which Gewobag is working together with the EIB. The project is not only in line with the EU Urban Agenda for livable and innovative cities, but also makes an important contribution to the EIB’s and Gewobag’s climate change objectives through high energy efficiency standards.
With around 70,000 apartments and more than 120,000 tenants, Gewobag is one of the largest real estate companies in the capital and nationwide. In the medium term, the state-owned housing company will expand its portfolio by around 15,000 apartments.
The EIB and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the signing of a €24.5 million financing agreement. The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19). In addition, it is also intended to support the potential expansion of the CALVID-1 trial into a confirmatory phase 3 trial and the commercial-scale manufacturing for IMU-838. Immunic AG, the German subsidiary of Immunic, Inc., will receive the EIB loan in three tranches upon the completion of pre-defined milestones.
The EIB and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. Atriva’s ATR-002, an oral small molecule, has been proven to block the viral propagation of SARS-CoV-2 in pre-clinical trials, making it a much-needed therapeutic option for patients with moderate to severe COVID-19 symptoms who require hospitalisation.
In response to the coronavirus pandemic, the EIB quickly deployed a support plan to support the European economy and help meet the most urgent financing needs of regions and municipalities. Recognizing the key role of cities and regions in mitigating the pandemic’s effects, the EIB approved exceptional measures to enable a faster approval and disbursement of new loans and allow more flexibility for the use and increase of ongoing loans.